ARTICLE | Company News
Crucell, National Institutes of Health infectious news
October 13, 2008 7:00 AM UTC
Crucell received an eight-year, $30 million contract from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to use its AdVac technology to develop a multivalent filovirus vaccine tha...